DSM has announced the retirement of Rob Routs as Chairman and member of the Board on 6 May 2021 as Thomas Leysen steps into the coveted role, held by routs for ten years.
The Board also has news of its own nominating Corien Wortmann-Kool to join as a new Supervisory Board member.
“I am proud that DSM is now well-positioned to capitalise on its long-term strategy, to use its science-based capabilities to create a positive impact and to deliver value for all stakeholders,” said Routs.
“I am pleased and feel very comfortable to hand-over to Thomas Leysen, whose experience will support DSM's leadership on the company's on-going journey to create brighter lives for all."
Co-CEOs of DSM, Geraldine Matchett and Dimitri de Vreeze said, "We would like to express our deep gratitude to Rob Routs for his guidance, challenge and collaboration, which have been invaluable to us throughout his tenure.
“We would especially like to thank him for staying an extra year to support the transition as we became Co-CEOs.”
Funk & Chime
Staying with corporate Boards, it was announced in late March that Marc Funk, ex-CEO of Lonza Group has joined China-based Chime Biologics’ Board of Directors.
"I am attracted by Chime Biologics' vision to make world-class biologics affordable and accessible to all patients globally through technology and manufacturing innovation,” said Funk.
“The global market for Contract Development and Manufacturing Organization (CDMO) is very promising and Chime Biologics has a very good track record, deep industry knowhow and strong market presence.”
Led by Executive Chairman of Chime Biologics James Huang, the firm provides outsourcing services for biopharmaceutical development and manufacturing.
Commenting on the appointment, Huang said, “We welcome Marc to join the Board of Directors of Chime Biologics and serve as a director."
"With his rich and outstanding professional knowledge and industry experience, we trust Marc could contribute a lot to the long-term strategic and business development of Chime Biologics."
Fellow Board Director Andrew Ng chimed in by adding, “We look forward to the guidance and support by a reputable and resourceful business leader and veteran in the global CDMO space like Marc himself.
“We also trust Marc could bring a lot of new development opportunities to Chime Biologics."
More high-level hiring taking place include those at Danone, where the board of the French food giant announced Gilles Schnepp as non-executive Chairman, while Veronique Penchienati-Bosetta and Shane Grant will serve as CEO and deputy CEO on an interim basis.
Schnepp replaces Emmanuel Faber as outgoing Chairman and CEO in response to shareholders who became increasingly concerned at the firm’s performance under the leadership of Faber, who became Chief Executive in 2014 and Chairman three years later.
“I have tremendous regard for Danone’s history and its contribution to society through its world leading healthy food and beverages, and commitment to sustainability,” said Schnepp.
“The priority of the Board is now to accelerate the process to recruit a new CEO, while Véronique and Shane continue to lead the business during this period.
“I look forward to working with the Board to support them in their interim roles, and the wider management team as they accelerate our efforts to create value for all our stakeholders.”
Finally, Swiss biotech company Evolva announces the appointment of Carsten Däweritz as Chief Financial Officer effective 16 April 2021.
“I'm honoured and excited to be given the opportunity to join one of the promising biotech businesses,” Carsten said.
Oliver Walker, CEO of Evolva, added, “I'm pleased that Carsten has accepted the role of CFO at Evolva.
“He has extensive leadership experience in financial positions. He has our full support and confidence as we continue to grow the business.”